** Shares of Hbm Holdings 2142.HK jump 7.8% to HK$14.87, their highest point since October 10

** Stock on track for a second session of gains, and marks its biggest intraday pct rise since September 30

** Co says its unit Nona Biosciences (Suzhou) has entered into a non-exclusive licence agreement with Pfizer PFE.N, which aims to accelerate preclinical antibody discovery across a range of potential disease indications

** Under the agreement, Pfizer will gain global rights to access Nona's proprietary HCAb platform to generate fully human heavy chain-only antibodies, while Nona will receive an upfront payment and is eligible for regulatory, clinical, and commercial milestone payments

** Nona may collaborate with Pfizer for antibody discovery, development, and engineering, company says

** YTD, Hbm stock up 676.9% and Hang Seng Biotech Index .HSBIO up 82.6%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))